Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p
about
Bortezomib for the treatment of multiple myelomaFirst-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesSalvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?First line vs delayed transplantation in myeloma: Certainties and controversiesMultiple myeloma cancer stem cellsEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisInterpretation of cytogenetic results in multiple myeloma for clinical practiceNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsFifty years of melphalan use in hematopoietic stem cell transplantationCurrent and emerging treatment options for patients with relapsed myelomaTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersIncidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysisMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementEuropean perspective on multiple myeloma treatment strategies in 2014Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementAdvances in the autologous and allogeneic transplantation strategies for multiple myelomaEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesNew criteria for response assessment: role of minimal residual disease in multiple myelomaPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyRecent advances in understanding multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyThe choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.The role of SLAMF7 in multiple myeloma: impact on therapy.Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaCarfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPhase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 studySubcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.Update on the optimal use of bortezomib in the treatment of multiple myeloma
P2860
Q24185881-302D6D31-9909-4C9C-BACC-65514FF808F3Q24197999-75456845-0BA2-440B-9DE9-6D518E87518FQ26740359-D6C6B2E4-68EF-4554-8B69-07F46C351132Q26745957-A2306CC6-5FDE-4B61-9A10-935D2E1549F8Q26752365-B57784D9-E722-4A52-B05A-DD19C298F75DQ26767418-C969ABFB-B1DC-4615-AC02-ACDC9BF9D197Q26777803-8BD1B427-87EE-4ACC-A765-FE3C02D6FBDFQ26822754-28072D09-4B84-48BF-88CB-979C39EF3F5AQ26824498-5A1024EF-9079-4951-A231-530A74B50D6CQ26830878-3283CD7B-5149-4648-8C48-2B10AEB18548Q26851202-E9AA3B3D-F01C-480A-9F6C-19622FA19F61Q26991817-BC2DEDBF-D9A2-46E1-8568-7EE1E684728FQ26998884-92A270BC-7BB3-495E-AC98-769A3DE5AB41Q27005966-E45C10DA-9949-4F53-9501-F0F7AB17B161Q27011865-48D96FC0-C844-4E8C-B711-F08ED15C10A1Q27014801-98184D0E-998F-43C6-8D9A-AF35D2EC6CF1Q27026478-14E52B61-D5E4-406B-8260-FFBBD2426E30Q27027512-4FC24E3A-D858-486D-98DB-859A2C2576F3Q28070090-AF2106B5-919F-4C62-BB6D-2FBA47C20119Q28070331-A451F289-AE61-48A7-B57F-00FC3C6E7B9BQ28082910-53061AEE-9B34-4864-BC66-DD58D2CD5EFEQ28539605-6A5CCA99-1FB3-492E-9524-9C649C449C1BQ30248842-361FACF3-4D86-4F1E-B37F-A8DDFD0E04A8Q30249167-C832C231-D57C-416E-8466-4C151140841AQ30275382-D7651738-3975-40A5-BAD9-A586BD5B2E74Q30409713-5E577DB3-BABE-4926-9EC8-EA436EBD55DCQ30424188-FD4363F2-DCBD-4B46-AEBC-42D5B28F607DQ30571858-26DCE314-61B8-43AB-BAE1-4863D4177390Q33401596-C7CECE88-F9A0-4863-8EDF-22F8211A13A9Q33405119-B86F3022-783B-41D1-902F-24EC579B61F4Q33405134-447E3487-9715-420A-AC00-B9B85D4144F0Q33405532-C20E2B87-12AB-4116-AA5D-DC76F334E452Q33410213-318805DD-E06D-45BC-B02E-50C2371E7932Q33412684-D03B09FD-A92D-4D60-AB50-25A2E78A8A61Q33415759-0729D4DE-F206-4B2A-9B34-D9A1DA0D1A90Q33415911-B162FA96-4C80-4CE0-AFD8-AE5053B38911Q33418098-F0EF1098-4AB3-46E0-9A73-31870F7333ABQ33425607-5A47C42F-F21E-4FC2-9BA1-1775FC457414Q33426372-73905FA5-3CB1-4780-878D-C6D66B12B418Q33440007-9710E329-BE46-4DC0-BF83-953EA3DD051D
P2860
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@en
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@nl
type
label
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@en
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@nl
prefLabel
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@en
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@nl
P2093
P50
P1433
P1476
Bortezomib with thalidomide pl ...... ltiple myeloma: a randomised p
@en
P2093
Antonio Ledda
Antonio Spadano
Claudia Cellini
Claudia Crippa
Elena Zamagni
Francesca Patriarca
GIMEMA Italian Myeloma Network
Giorgio Lambertenghi Deliliers
Lucia Pantani
Maria Teresa Petrucci
P304
P356
10.1016/S0140-6736(10)61424-9
P407
P50
P577
2010-12-09T00:00:00Z